8-K: Barinthus Bio's VTP-300 Shows Promise in Hepatitis B Trials, Achieving Undetectable Viral Levels

Barinthus Biotherapeutics announced positive interim data from two clinical trials of its VTP-300 therapy for chronic hepatitis B, demonstrating significant reductions in viral load and potential for treatment discontinuation.

Summary

• Barinthus Biotherapeutics presented updated data from two clinical trials, HBV003 and IM-PROVE II, at the European Association for the Study of the Liver (EASL) Congress 2024.
• The HBV003 trial, evaluating VTP-300 with low-dose nivolumab, showed sustained HBsAg declines, with some participants reaching undetectable levels.
• In the HBV003 trial, 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation, and 19% achieved undetectable HBsAg at any time.
• The IM-PROVE II trial, in partnership with Arbutus Biopharma, tested imdusiran followed by VTP-300, showing a statistically significant difference in HBsAg levels compared to placebo at 24 weeks post-treatment.
• In the IM-PROVE II trial, 84% of participants in the VTP-300 group met criteria for NUC discontinuation at the end of treatment, compared to 52% in the placebo group.
• The company expects the next data cut for both trials in the fourth quarter of the year, which will include data from a triple combination approach in the IM-PROVE II trial.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with strong efficacy signals and good tolerability, suggesting a promising future for the company's hepatitis B program. The company also has a strong cash position.

Positives

• Both VTP-300 trials showed the treatment was generally well-tolerated with no serious adverse events related to the treatment.
• The data suggests VTP-300 could be a critical component of a functional cure regimen for chronic hepatitis B.
• The trials demonstrated robust T cell responses to all encoded antigens.
• The IM-PROVE II trial showed a statistically significant difference in HBsAg levels between the VTP-300 treatment group and the placebo group at 24 weeks post-treatment.
• The company has a strong cash position of $130 million as of March 31, 2024, with an estimated cash runway into Q4 2025.

Negatives

• In the HBV003 trial, thyroid dysfunction was reported in 9% of participants, though most had normal thyroid function tests at their last visit.
• Transient alanine transaminase (ALT) elevations occurred in 14 participants in the HBV003 trial through to Day 85.
• One participant in the HBV003 trial discontinued treatment due to an adverse event.

Risks

• The company's forward-looking statements are subject to numerous risks and uncertainties, including the success, cost, and timing of clinical trials.
• There is a risk that interim or topline data may not reflect final data or results.
• Global economic uncertainty, including disruptions in the banking industry, and geopolitical conflicts could impact the company's operations.
• The company's ability to fund operations and access capital is subject to risks and uncertainties.

Future Outlook

The company anticipates further data readouts from the VTP-300 trials in Q4 2024, including data from a triple combination approach. They also plan to initiate a Phase 1 trial for VTP-1000 in celiac disease in Q3 2024.

Management Comments

• Bill Enright, CEO of Barinthus Bio, stated that the data is further evidence that VTP-300 could be a critical component of a functional cure regimen.
• Prof. Man-Fung Yuen expressed encouragement about the potential of VTP-300 to provide sustained viral suppression and a potential functional cure.
• Dr. Nadege Pelletier, CSO of Barinthus Bio, highlighted the role of VTP-300 in maintaining low HBsAg levels and the therapeutic potential of the combination approach with imdusiran.

Industry Context

The announcement is significant in the context of the ongoing efforts to find a functional cure for chronic hepatitis B, a disease affecting millions globally. The results position Barinthus Bio as a key player in the development of novel immunotherapies for this condition.

Comparison to Industry Standards

• Current standard treatments for chronic hepatitis B, such as nucleos(t)ide analogues, often require lifelong therapy and have low cure rates, with less than 10% of patients achieving a functional cure.
• Pegylated interferon, another treatment option, has significant side effects.
• The results from the VTP-300 trials, particularly the high rates of HBsAg reduction and NUC discontinuation eligibility, suggest a potential improvement over existing therapies.
• The combination approach with imdusiran in the IM-PROVE II trial shows promise in achieving sustained viral suppression, which is a key goal in hepatitis B treatment.
• The company's approach of using antigen-specific immunotherapies to guide T-cells is a novel approach compared to traditional antiviral therapies.

Stakeholder Impact

• Shareholders may see a positive impact due to the promising clinical trial results.
• Patients with chronic hepatitis B may benefit from the development of a potential functional cure.
• Employees may be motivated by the positive progress of the company's research and development efforts.

Next Steps

• The company will continue to monitor HBsAg declines in the VTP-300 treatment group.
• The next data cut for both trials is expected in the fourth quarter of the year.
• The company plans to initiate a Phase 1 trial for VTP-1000 in celiac disease in Q3 2024.

Key Dates

Keywords

VTP-300, Hepatitis B, Chronic Hepatitis B, Immunotherapy, HBsAg, Nivolumab, Imdusiran, Clinical Trials, T cell, Nucleos(t)ide analogue, Functional Cure